Respiratory motion correction method based on principal components analysis model for liver contrast-enhanced ultrasound sequences / 医疗卫生装备

Objective To relieve the influences of the respiratory motion on the liver contrast-enhance ultrasound (CEUS) image sequences,to enhance the quantitative analysis accuracy for liver CEUS and to put forward a correction strategy for the respiratory motion in liver CEUS sequences.Methods A principal component analysis (PCA) model of the respiratory motion in liver CEUS sequences was established with 18 cases of rabbit liver VX2 tumors,and a respiratory motion curve was generated based on the principal component with large data proportion,then the images with similar phases to the reference image were analyzed.Resnlts Correction made the mean structural similarity and mean correlation coefficient enhanced significantly to 0.57±0.11 and 0.78±0.11 respectively (P＜0.001),while the average of deviation valve (DV) was decreased to 29.9±7.02 which only was one-third of the original value.Threshold setting could further improve the quality of the selected image sequence.Conchusion The proposed respiratory motion method proves its effectiveness for rabbit liver CEUS image sequences,and thus contributes to enhancing the differential diagnosis rate of benign and malignant liver tumors.

Respiratory motion correction method based on principal components analysis model for liver contrast-enhanced ultrasound sequences / 医疗卫生装备

Objective To relieve the influences of the respiratory motion on the liver contrast-enhance ultrasound (CEUS) image sequences,to enhance the quantitative analysis accuracy for liver CEUS and to put forward a correction strategy for the respiratory motion in liver CEUS sequences.Methods A principal component analysis (PCA) model of the respiratory motion in liver CEUS sequences was established with 18 cases of rabbit liver VX2 tumors,and a respiratory motion curve was generated based on the principal component with large data proportion,then the images with similar phases to the reference image were analyzed.Resnlts Correction made the mean structural similarity and mean correlation coefficient enhanced significantly to 0.57±0.11 and 0.78±0.11 respectively (P＜0.001),while the average of deviation valve (DV) was decreased to 29.9±7.02 which only was one-third of the original value.Threshold setting could further improve the quality of the selected image sequence.Conchusion The proposed respiratory motion method proves its effectiveness for rabbit liver CEUS image sequences,and thus contributes to enhancing the differential diagnosis rate of benign and malignant liver tumors.

Inhibitory Effect of Curcumin on Proliferation of CD34(+) Acute Myeloid Leukemia Cells and Its Mechanism / 中国实验血液学杂志

<p><b>OBJECTIVE</b>To explore the inhibitory effect of curcumin on proliferation of CD34(+) acute myeloid leukemia cells and its mechamism.</p><p><b>METHODS</b>KG1a and Kasumi-1cell lines were treated with curcumin of different concentrations (0, 40, 60, 80 µmol/L). The effect of curcumin on cell viability and proliferation was detected by trypan blue staining and cell count. The effect of curcumin on distribution of NF-κB P65 subunit was analyzed by immunofluorescence and Western blot.</p><p><b>RESULTS</b>The curcumin inhibited proliferation of KG1a and Kasumi-1 cells in a dose-dependent manner. Western blotting showed that curcumin led to significant down-regulation of NF-κB P65 nuclear protein expression. Immunofluorescence assay showed that treatment with 40 µmol/L of curcumin for 48h suppressed the nuclear translocation of NF-κB p65 in KG1a and Kasumi-1 cells.</p><p><b>CONCLUSION</b>The curcumin suppresses cell growth of KG1a and Kasumi-1 cells, its mechanism may be related to inhibitory effect of curcumin on NF-κB p65 nucleus protein.</p>

Analysis of outocome of pirarubicin-based combination chemotherapy regimen in the treatment of newly diagnosed acute myeloid leukemia-a prospective, open, randomized and multicenter clinical trial / 中华血液学杂志

<p><b>OBJECTIVE</b>To compare the effectiveness and side effects of two chemotherapy regimens [pirarubicin + cytarabine (TA) and daunorubicin + cytarabine (DA)] in patients with acute myeloid leukemia (AML).</p><p><b>METHODS</b>From Oct 2006 to Jul 2009, there were 207 newly diagnosed AML patients randomized into DA or TA group from 72 centers all over the country. The aim of this clinical trial is to observe and evaluate complete remission rate (CR), total remission rate (TRR), and side effect after one or two circles of therapy.</p><p><b>RESULTS</b>In 198 evaluable patients, 126 cases in TA group and 72 in DA group were evalvable, with a ratio of 1.75:1. CR was 69.8% and TRR (CR + PR) was 81.8% in TA group and 63.9%, 80.9% in DA group, correspondingly (P > 0.05). For patients with subtype M(2), CR (77.1%) in TA group was higher than that in DA (60%). There was no difference in side effect between the two groups.</p><p><b>CONCLUSION</b>There is no difference of the effect between TA and DA chemotherapy for newly diagnosed AML patients. But for subtype M(2), TA is more efficacy. And there is no difference in side effect between the two regimens.</p>

Combined effect of TNF-related apoptosis induced ligand and Ara-C in inducing apoptosis of HL-60 cells and its mechanism / 中国实验血液学杂志

To investigate the combined effect of human recombinant soluble TNF-related apoptosis induced ligand (hrsTRAIL) with Ara-C or alone on HL-60 leukemia cell lines and its mechanism, human leukemia cell lines HL-60 were cultured in vitro. HL-60 cells were divided into 5 groups: control group, Ara-C group, rsTRAIL group, Ara-C + rsTRAIL simultaneously given group, Ara-C + rsTRAIL tandem given group (Ara-C followed by rsTRAIL group). The cytotoxic effect was measured by MTT assay; cell apoptosis rate was determined by flow cytometry after Annexin V/PI staining; the expression level of DR5 on surface of HL-60 cells treated with Ara-C at different concentrations for 24 hours was determined by flow cytometry. The expression level of DR5 on surface of HL-60 cells and caspase-8 activity in HL-60 cells of rsTRAIL group and Ara-C + rsTRAIL tandem group was determined by flow cytometry. The result showed that rsTRAIL could inhibit the proliferation of HL-60 cells and induce apoptosis of HL-60 cells in a concentration-dependent manner. The apoptosis rate of HL-60 cells in Ara-C + rsTRAIL tandem given group was higher than that in Ara-C + rsTRAIL simultaneously given group, the expression level of DR5 on surface of HL-60 cells and intracellular activity of caspase-8 in Ara-C + rsTRAIL tandem given group were higher than those in rsTRAIL group. When HL-60 cells treated with 5 and 10 mg/L of Ara-C for 24 hours, the expression level of DR5 on surface of HL-60 cells was higher than that in control group. It is concluded that rsTRAIL can inhibit the proliferation of HL-60 cells, and induce apoptosis of HL-60 cells. Ara-C can upregulate DR5 expression on the surface of HL-60 cells and enhance the effect of rsTRAIL-inducing apoptosis. Tandem treatment of HL-60 cells with Ara-C followed by rsTRAIL induce more apoptosis than that of co-treatment with rsTRAIL and Ara-C. Ara-C and rsTRAIL has a synergistic inhibitory effect on growth of HL-60 cells. The mechanism may correlate with up-regulation of the expression level of DR5 and/or caspase-8 in HL-60 cells by Ara-C.